Research ExplorerPublicationsFingolimod - ein neuer Immunmodulator

Fingolimod - ein neuer Immunmodulator

Standard

Fingolimod - ein neuer Immunmodulator. / Friedrich, F W; Eschenhagen, T.

In: DEUT MED WOCHENSCHR, Vol. 134, No. 42, 01.10.2009, p. 2127-31.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Friedrich, FW & Eschenhagen, T 2009, 'Fingolimod - ein neuer Immunmodulator', DEUT MED WOCHENSCHR, vol. 134, no. 42, pp. 2127-31. https://doi.org/10.1055/s-0029-1241903

APA

Friedrich, F. W., & Eschenhagen, T. (2009). Fingolimod - ein neuer Immunmodulator. DEUT MED WOCHENSCHR, 134(42), 2127-31. https://doi.org/10.1055/s-0029-1241903

Vancouver

Friedrich FW, Eschenhagen T. Fingolimod - ein neuer Immunmodulator. DEUT MED WOCHENSCHR. 2009 Oct 1;134(42):2127-31. https://doi.org/10.1055/s-0029-1241903

Bibtex

@article{08c098fbccf3488e8fb5371cb650d92a,
title = "Fingolimod - ein neuer Immunmodulator",
abstract = "Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingolimod compared to interferon beta, glatirameracetate and natalizumab is its oral availability. Definitive assessment of the compound has to await the results of trials currently being performed.",
keywords = "Biological Availability, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Transplantation, Multiple Sclerosis, Propylene Glycols, Sphingosine",
author = "Friedrich, {F W} and T Eschenhagen",
note = "Copyright Georg Thieme Verlag KG Stuttgart . New York.",
year = "2009",
month = oct,
day = "1",
doi = "10.1055/s-0029-1241903",
language = "Deutsch",
volume = "134",
pages = "2127--31",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "42",

}

RIS

TY - JOUR

T1 - Fingolimod - ein neuer Immunmodulator

AU - Friedrich, F W

AU - Eschenhagen, T

N1 - Copyright Georg Thieme Verlag KG Stuttgart . New York.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingolimod compared to interferon beta, glatirameracetate and natalizumab is its oral availability. Definitive assessment of the compound has to await the results of trials currently being performed.

AB - Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingolimod compared to interferon beta, glatirameracetate and natalizumab is its oral availability. Definitive assessment of the compound has to await the results of trials currently being performed.

KW - Biological Availability

KW - Graft Rejection

KW - Humans

KW - Immunosuppressive Agents

KW - Kidney Transplantation

KW - Multiple Sclerosis

KW - Propylene Glycols

KW - Sphingosine

U2 - 10.1055/s-0029-1241903

DO - 10.1055/s-0029-1241903

M3 - SCORING: Zeitschriftenaufsatz

C2 - 19809964

VL - 134

SP - 2127

EP - 2131

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 42

ER -